Johnson & Johnson: Spravato Approved in the U.S. as the First and Only Monotherapy for Adults With Treatment-Resistant Depression
January 23, 2025
January 23, 2025
NEW BRUNSWICK, New Jersey, Jan. 23 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours/1
SPRAVATO alone showed a rapid and superior improvement vs. placebo in the Montgomery-Asberg Depression Rating Scale (M . . .
* * *
Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours/1
SPRAVATO alone showed a rapid and superior improvement vs. placebo in the Montgomery-Asberg Depression Rating Scale (M . . .